Plain-English translation of NCT05822362 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing (CBD)—a compound derived from hemp—to see if it can help protect brain health and slow memory decline in people with mild cognitive impairment. Researchers want to understand whether two different forms of CBD, with or without a small amount of THC (another cannabis compound), work better than a placebo at improving thinking skills, sleep, anxiety, and other measures of brain health. You would take the medication daily for 24 weeks while researchers monitor how it affects your cognition and overall well-being.
As people age, some experience mild memory and thinking problems that can be an early warning sign of Alzheimer's disease. Doctors currently have limited treatment options to slow this decline, so researchers are testing whether this medication might help protect the brain and preserve cognitive function.
You likely qualify if…
You likely don't qualify if…
You would be randomly assigned to take one of three daily treatments for 24 weeks: a full-spectrum CBD supplement with trace THC, a CBD supplement without THC, or a placebo (a treatment with no active ingredient). Throughout the study, you would visit the research site multiple times for cognitive testing, blood draws, and other health assessments to measure how the treatment affects your thinking, sleep, mood, and biomarkers of brain health. A family member or friend would also participate in some check-ins to help track your progress.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
United States
Phase
Testing effectiveness
Sponsor
University of Colorado, Denver
Enrollment target
~236 participants
Started
January 2024
Primary completion
April 2028
Age range
55 Years – 85 Years
Last updated on clinicaltrials.gov in June 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Raeghan Mueller, PhD
University of Colorado, Denver
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.